Allon’s CEO Presenting at BIO-Europe Spring
VANCOUVER, BRITISH COLUMBIA–(Marketwire – Mar 9, 2010) – Allon Therapeutics Inc. (TSX:NPC) President and CEO Gordon McCauley will benefaction an refurbish of the Company’s blurb operation swell on Wednesday, Mar 10 at 11:15 CET at the BIO-Europe Spring 2010 4th Annual International Partnering Conference in Barcelona, Spain.
BIO-Europe Spring attracts general government team from determined and biotech companies, curative companies, monetary firms with imagination in the biotech sector, and in isolation investors. Presenting companies make use of the discussion to brand brand new blurb operation opportunities and to rise vital relationships. The discussion is sponsored by EBD Group, a heading partnering organisation for the tellurian hold up scholarship attention with offices in Canada, the United States, the United Kingdom and Switzerland.
In this presentation, McCauley will embody an refurbish of Allon’s clinical module to rise lead neuroprotective drug claimant davunetide as the initial authorized diagnosis for frontotemporal insanity (FTD), a organisation of fast on-going and deadly degenerative brain diseases, mostly mis-diagnosed as Parkinson’s or Alzheimer’s disease.
On Jan 26th and Jan 28th, Allon voiced the derivation of dual clinical trials in the FTD program. In addition, the Company voiced Jan 12th that the United States Food and Drug Administration (FDA) postulated Orphan Drug Designation to davunetide for the diagnosis of on-going supranuclear palsy (PSP), one sort of multiform sorts of FTD in that the pathology is well well well well known to engage spoil of the brain protein tau.
Davunetide’s intensity as a diagnosis for PSP and alternative tau dementias has been reliable in animal studies and in a Phase 2 tellurian clinical hearing with patients with amnestic amiable cognitive spoil (aMCI), a predecessor to Alzheimer’s in that the neuropathology additionally involves tau impairment.
Allon voiced Mar 3, 2010 that it has entered in to a $10 million three-year standby equity placement agreement (SEDA) with YA Global Master SPV Ltd., a account managed by Yorkville Advisors, LLC. This equity trickery provides the Company with a flexible, low-cost source of capital, in an amount, and at the time of Allon’s choosing, with a built-in smallest price.
About davunetide
Davunetide is subsequent from a of course occurring neuroprotective brain protein well well well well known as wake up contingent neuroprotective protein (ADNP). Allon’s laboratory and animal studies have shown that davunetide improves discernment in a series of mildew models by a resource believed to engage goods on structures in the brain – well well well well known as microtubules that have been vicious to report exchnage in between brain cells and the make up of particular cells.
In 2008, Allon reported Phase IIa clinical hearing formula display that davunetide had a statistically poignant certain stroke on mental recall duty in patients with amnestic amiable cognitive spoil (aMCI), a predecessor to Alzheimer’s mildew (AD). The interpretation was presented Jul twenty-eight and Jul 30, 2008 to the International Conference on Alzheimer’s Disease and Related Disorders (ICAD 2008).
On Dec 7, 2009, Allon reported Phase IIa clinical hearing formula display that davunetide softened mental recall duty of schizophrenia patients and had a certain stroke on the capability of these patients to lift out critical activities in their every day lives. The interpretation was presented at the annual assembly of the American College of Neuropsychopharmacology.
About Allon’s neuroprotective platforms
Allon’s dual neuroprotective record platforms have been formed on dual of course occurring proteins constructed by the brain in reply to a operation of insults. The platforms have been activity-dependent neuroprotective protein (ADNP) and activity-dependent neurotrophic means (ADNF).
Because the dual platforms have been formed on opposite proteins, the drug from any have been opposite molecules with opposite healing mechanisms and graphic blurb opportunities. Clinical-stage drug formed on davunetide have been subsequent from ADNP, whilst preclinical theatre drug AL-309 is subsequent from ADNF. Davunetide is focused on Alzheimer’s disease, cognitive spoil in schizophrenia, and frontotemporal dementia. ADNF drug claimant AL-309 is being grown for the diagnosis of marginal neuropathies and is administered orally or subcutaneously.
About Allon
Allon Therapeutics Inc. is a clinical-stage biotechnology association building treatments for vital neurodegenerative conditions. Allon’s drug davunetide has demonstrated tellurian efficiency in amnestic amiable cognitive impairment, a predecessor to Alzheimer’s disease, and cognitive spoil compared with schizophrenia. Allon has Phase II tellurian efficiency programs posterior large underserved markets, such as Alzheimer’s mildew and cognitive spoil compared with schizophrenia, and in waif markets, such as frontotemporal dementias. The Company is listed on the Toronto Stock Exchange underneath the trade pitch “NPC” (Neuro Protection Company™) and formed in Vancouver. For one more report greatfully revisit the Company’s website: www.allontherapeutics.com.
Forward Looking Statements
Statements contained herein, alternative than those that have been particularly statements of chronological actuality might embody forward-looking information. Such statements will typically enclose difference such as “believes”, “may”, “plans”, “will”, “estimate”, “continue”, “anticipates”, “intends”, “expects”, and identical expressions. While forward-looking statements paint management’s opinion formed on assumptions that government believes have been reasonable, forward-looking statements by their inlet have been theme to well well well well known and opposite risks, uncertainties and alternative factors that might means the tangible results, events or developments to be materially opposite from any destiny results, events or developments voiced or pragmatic by them. Such factors include, between others, the fundamental doubt concerned in systematic investigate and drug development, Allon’s early theatre of development, miss of product revenues, the one more collateral requirements, the risks compared with successful execution of clinical trials and the prolonged lead-times and tall costs compared with obtaining regulatory capitulation to marketplace any product that Allon might in the future develop. Other risk factors embody the singular protections afforded by egghead skill rights, fast record and product obsolescence in a rarely rival sourroundings and Allon’s coherence on collaborative partners and stipulate investigate organizations. These factors can be reviewed in Allon’s open filings at www.SEDAR.com and should be deliberate carefully. Readers have been cautioned not to place unjustified faith on such forward-looking statements.
